Tokyo, November 12, 2026 – Trustar Capital Partners Limited (“Trustar Capital”) announces that Trustar Capital Japan Fund III (“Fund”) has contracted a share transfer agreement with Kurabo Industries Ltd. (“KURABO”, Stock Code: 3106 (TSE Prime)) in which Fund will transfer a portion of its shares (16,400,000 shares, 15.4％ of total number of issued shares) in TAUNS Laboratories, Inc. (“TAUNS ”, Stock Code: 197A (TSE Standard); a company engaged in the development, manufacture, and sale of in vitro diagnostic medical devices, research reagents, and other products; Headquarters: Izunokuni City, Shizuoka Prefecture; President and CEO: Masaki Nonaka) to KURABO on November 30th, 2026 (“Share Transfer”).
With this Share Transfer, etc., TAUNS and KURABO have made an agreement of capital and business alliance and TAUNS will be treated as an equity-method affiliate of KURABO.
TAUNS possesses advanced technical capabilities and production capacity in the development, manufacture, and sale of in vitro diagnostic medical devices, primarily in the field of infectious diseases, and has established a solid business foundation as one of Japan’s leading diagnostic reagent manufacturers.
Meanwhile, KURABO has positioned the Life Science and Technology business as one of its core focus areas in its medium-term management plan, “Accelerate ’27,” and is working to develop new business areas and strengthen its business foundation.
The environment surrounding the in vitro diagnostic industry is undergoing significant changes driven by technological innovation, against the backdrop of growing demand not only for infectious disease testing but also for early diagnosis, preventive medicine, and personalized medicine. Recognizing that achieving sustainable growth in this environment requires not only individual initiatives by each company but also strategic collaboration that leverages each company’s strengths, TAUNS and KURABO will work to expand both companies’ business domains and strengthen their competitiveness. They will do so by mutually utilizing their respective technologies, R&D capabilities, manufacturing know-how, sales networks, and human resources to create new products and services, strengthen production systems, and expand sales opportunities.
Since our investment in July 2016, we have worked closely with TAUNS and its management team. TAUNS, which has achieved remarkable growth since our investment, is expected to experience further development through this capital and business alliance with KURABO. As a shareholder, we will continue to support TAUNS’ further growth. We ask for your continued support for both TAUNS and KURABO.
Ends
TAUNS Laboratories, Inc.
Established: 1987
Stock Code: 197A (Tokyo Stock Exchange Standard Market)
Representative: Masaki Nonaka, President and CEO
Headquarters: 761-1 Kamishima, Izunokuni City, Shizuoka Prefecture, Japan
Website: https://www.tauns.co.jp/
Kurabo Industries Ltd.
Founded: 1888
Stock Code: 3106 (Tokyo Stock Exchange Prime Market)
Representative: Shinji Nishigaki, President and CEO
Headquarters Address: 2-4-31 Kyutaro-machi, Chuo-ku, Osaka, Japan
Website: https://www.kurabo.co.jp/
Trustar Capital Partners Limited
Trustar Capital Partners Limited operates a global private equity fund business with a primary focus on Japan and other parts of Asia.
Trustar Capital Japan Fund has provided hands-on support to mid-sized Japanese companies with strong brands and technological capabilities, fostering their growth. Since its establishment in 2004, the fund has made 17 investments.
Website: (Japanese) http://www.trustarcapital.jp/
(English) http://www.trustarcapital.com/
For media enquiries, please contact:
Cindy TAM
Director, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6813
cindytam@citiccapital.com
Irene GAO
Senior Associate, Corporate Relations
CITIC Capital Holdings Limited
Tel: +852 3710 6814
irenegao@citiccapital.com
Takato FUKUDA
Director
Trustar Capital Partners Japan Limited
Tel: +81 3 5211-3830